Business Wire

ROBOSENSE

2.3.2023 15:06:52 CET | Business Wire | Press release

Share
RoboSense Launches RS-Fusion-P6, Automotive-Grade Solid-State LiDAR Perception Solution for L4 Autonomous Driving

RoboSense, a world-leading provider of Smart LiDAR Sensor Systems, has announced the launch of its first automotive-grade solid-state LiDAR perception solution for L4 autonomous driving, the RS-Fusion-P6 (P6). With advanced software and hardware support from RoboSense, the P6 provides precise and intelligent environmental perception capabilities, enabling autonomous vehicles to navigate through complex driving scenarios with ease, helping to reduce costs and increase efficiency, and promoting the rapid implementation of large-scale autonomous driving commercial operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230302005545/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

RS-Fusion-P6 (Photo: Business Wire)

As an automotive-grade solid-state LiDAR perception solution, the P6 perfectly integrates hardware based on two-dimensional MEMS scanning technology and software based on artificial intelligence technology, fully demonstrating the leading level of RoboSense's core technologies in the areas of chips, hardware, and software.

RoboSense's RS-Fusion-P6 solution is designed to be flexible and scalable, making it suitable for a wide range of autonomous driving applications. It can be customized to meet the specific needs of different vehicle platforms and applications, providing a high level of performance and accuracy for all types of autonomous driving scenarios.

The P6 offers high-performance perception capabilities for full-scene environments from start to finish, making it ideal for a range of driving scenarios, including city streets, highways, and everything in between. Equipped with the four M-series solid-state LiDARs, the P6 offers dynamic switching and high-resolution long-distance detection capabilities, enabling intelligent perception over a 360-degree horizontal range, and allowing it to detect traffic conditions up to 200 meters away. The P6 can quickly process this data and provide feedback to the autonomous driving control center, allowing the vehicle to react in milliseconds to any changes in the driving environment.

P6 is equipped with RoboSense self-developed real-time point cloud perception software Perception. Under the intelligent processing of perception, P6 will be able to accurately process complex traffic environment information. Even in challenging driving scenarios, such as mixed traffic and inclement weather conditions, the P6 can accurately identify pedestrians, electric vehicles, cars, trucks, and other obstacles while tracking their speed, acceleration, and location. With this precise environmental perception data, autonomous vehicles equipped with the P6 can make accurate judgments and perform corresponding actions in real-time.

The launch of the P6 demonstrates RoboSense's deep understanding of the pain points in the autonomous driving industry. As the automotive industry continues to rapidly evolve, the P6 provides a reliable and high-performance perception solution that can help to accelerate the adoption of autonomous driving technology. With the P6, RoboSense further expands its product portfolio, which includes mechanical and solid-state LiDAR sensors, perception software, and integrated sensing solutions.

With its advanced perception capabilities and robust product portfolio, RoboSense is well-positioned to help accelerate the adoption of autonomous driving technology across a range of industries, including transportation, logistics, and mobility.

Full article of P6 in detail: https://www.robosense.ai/en/news-show-1690

About RoboSense
RoboSense (Suteng Innovation Technology Co., Ltd.) is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230302005545/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release

Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit

Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse

Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye